Investors & News

Latest News

March 03, 2020
FDA Grants Rare Pediatric Disease Designation to Stealth BioTherapeutics for Elamipretide for the Treatment of Barth Syndrome
February 27, 2020
Stealth BioTherapeutics to Present at 40th Annual Cowen Health Care Conference
February 18, 2020
Stealth BioTherapeutics Announces Positive Results From Study to Evaluate Efficacy of Elamipretide in Barth Patients Compared to Natural History Control
All News

Stock Quote (MITO)

Share

Why invest?

Our Company

Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging.

Our Programs

We are investigating our lead product candidate in late stage clinical studies in three primary mitochondrial diseases – primary mitochondrial myopathy, Barth syndrome and Leber’s hereditary optic neuropathy – as well as an earlier stage clinical study in dry age-related macular degeneration.

Our Pipeline

We continue to expand our broad knowledge of mitochondrial biology and novel chemistries, and advance our mitochondrial platform of late-stage clinical programs and pipeline candidates.

Latest Reports

March 14, 2019
6-K Report of Foreign Private Issuer
HTML
February 14, 2019
Stealth BioTherapeutics Prospectus
HTML
Reports

Latest Presentations

February 26, 2020
Investor Presentation March 2020
February 18, 2020
Barth Syndrome Efficacy Study Using Natural History Data as a Control
Presentations

Events

March 04, 2020
Stealth BioTherapeutics Presentation at 40th Annual Cowen Health Care Conference
at 10:40 am ET
Webcast
February 18, 2020
Barth Syndrome Efficacy Study Using Natural History Data as a Control
8:30 AM ET
Webcast
Financial Calendar
Media Relations

Amelia Stetler, 617-762-2562
media@stealthbt.com

Investor Inquiries
Stern IR
Lauren Stival, 212-362-1200
IR@stealthbt.com